07:13 PM
Tuesday 18 January 2022
Books – Ahmed Gomaa:
The Scientific Committee to Combat Corona at the Ministry of Health has approved a number of amendments to the protocol for treating “Covid-19” patients.
According to the sixth version of the treatment protocol, which was approved last December and obtained by Masrawy, the amendments include adding the drug “Baricitinib” to treat severe and critical cases in various isolation hospitals, which may need to be placed on respirators, or entry to intensive care.
The drug is part of a class of drugs called Janus kinase (JAK) inhibitors that suppress excessive stimulation of the immune system, and was recommended by the World Health Organization this month.
The new amendment also included adjusting the doses of the drug “Sarilumab”, which is a synthetic antibody, called “monoclonal” and belongs to a family called “interleukin-6 antigens”, recommended by the World Health Organization since July 2021 for the most serious cases as well.
The protocol determined the required doses for cases of infection, which were divided into mild cases, which are those without pneumonia or hypoxia, and the medium ones that suffer from pneumonia without hypoxia.
As for severe cases, they are those who suffer from pneumonia with hypoxia and respond to oxygen therapy, while critical cases are defined as those who suffer from pneumonia with hypoxia that does not respond to oxygen therapy.
treatment protocol
The protocol stipulated the treatment of mild cases infected with corona, by giving “hydroxychloroquine 400 mg twice on the first day, after that 200 mg twice for 6 days,” or giving “ivermectin 6 mg” (36 mg on the first, third, and sixth days), Or the drug “Favipiravir” 1600 twice daily on the first day, then 600 mg twice daily,” in addition to giving vitamins.
As for the average cases, they are patients with symptoms of pneumonia on radiographs, or a lack of white blood cells, and then the protocol stipulated the possibility of giving two classes of drugs together, whether “Hydroxychloroquine + Ivermectin”, or “Favipiravir + Ivermectin”, as well as Remdesivir for high-risk cases.
The recovered plasma can be used before the twelfth day of infection.
She also described treatment with monoclonal antibodies, in moderate cases with any risk factor, to prevent progression to severe disease.
For severely infected cases, it is directed to confine them to the care beds and give them the appropriate treatment protocol.
This protocol includes giving drugs: Remdesivir, with other drugs such as “Colchicine”, which clinical trials have shown to be effective in treating Covid-19 patients and reducing the risk of complications from the disease, as well as treatment with recovered plasma that can be used before the 12th day of infection.
This is in addition to the drug “tocilizumab”, a drug for rheumatoid arthritis, sold under the trade name “Actmera”, as well as the drug “Baricitinib”, which must be used with the drug remdesivir.
.